Safety, tolerability, and pharmacokinetics of single‐ and multiple‐dose administration of islatravir (MK‐8591) in adults without HIV-Reference-Cited by-同舟云学术

Safety, tolerability, and pharmacokinetics of single‐ and multiple‐dose administration of islatravir (MK‐8591) in adults without HIV

Published:2021-08-31 Issue:5 Volume:14 Page:1935-1944
ISSN:1752-8054
Container-title:Clinical and Translational Science
language:en
Short-container-title:Clinical Translational Sci

Author:

Matthews Randolph P.¹,Ankrom Wendy¹,Friedman Evan¹,Jackson Rudd Deanne¹,Liu Yang¹,Mogg Robin¹,Panebianco Deborah¹,De Lepeleire Inge²,Petkova Magdalena³,Grobler Jay A.¹,Stoch Selwyn Aubrey¹,Iwamoto Marian¹

Affiliation:

1. Merck & Co., Inc. Kenilworth New Jersey USA

2. MSD (Europe) Inc. Brussels Belgium

3. SGS Life Science Services Clinical Pharmacology Unit Antwerpen Antwerpen Belgium

Funder

Merck Sharp and Dohme

Publisher

Wiley

Subject

General Pharmacology, Toxicology and Pharmaceutics,General Biochemistry, Genetics and Molecular Biology,General Medicine,General Neuroscience

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cts.13048

Reference25 articles.

1. DHHS.Panel on Antiretroviral Guidelines for Adults and Adolescents Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Department of Health and Human Services 2019.https://clinicalinfo.hiv.gov/sites/default/files/inline‐files/AdultandAdolescentGL.pdf. Accessed October 2020.

2. UNAIDS.Joint United Nations Programme on HIV/AIDS (UNAIDS) FactSheet ‐ Global AIDS Update 2020 2020.https://www.unaids.org/sites/default/files/media_asset/UNAIDS_FactSheet_en.pdf. Accessed October 2020.

3. EACS.Guidelines for the management of people living with HIV (PLWH) in Europe. Version 10.1.2020.https://www.eacsociety.org/files/guidelines‐10.1.finalsept2020.pdf. Accessed October 2020.

4. CDC.Centers for Disease Control and Prevention (CDC) US Public Health Service: Preexposure prophylaxis for the prevention of HIV infection in the United States ‐ 2017 Update. A Clinical Practice Guideline.2018.https://www.cdc.gov/hiv/pdf/risk/prep/cdc‐hiv‐prep‐guidelines‐2017.pdf. Accessed October 2020.

5. Antiretroviral resistance testing in HIV‐positive people;Aves T;Cochrane Database Syst Rev,2018

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Intracellular islatravir-triphosphate half-life supports extended dosing intervals;Antimicrobial Agents and Chemotherapy;2024-09-04

2. Current status of the small molecule anti-HIV drugs in the pipeline or recently approved;Bioorganic & Medicinal Chemistry;2024-09

3. Modeling of HIV‐1 prophylactic efficacy and toxicity with islatravir shows non‐superiority for oral dosing, but promise as a subcutaneous implant;CPT: Pharmacometrics & Systems Pharmacology;2024-08-20

4. Thorough QT/QTc study to evaluate the effect of a single supratherapeutic dose of islatravir on QTc interval prolongation in healthy adults;Antimicrobial Agents and Chemotherapy;2024-08-07

5. Consensus recommendations for use of long‐acting antiretroviral medications in the treatment and prevention of HIV‐1: Endorsed by the American Academy of HIV Medicine, American College of Clinical Pharmacy, Canadian HIV and Viral Hepatitis Pharmacists Network, European AIDS Clinical Society, and Society of Infectious Diseases Pharmacists;Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy;2024-07